Pooled EMERGENT Data: KarXT Delivers Moderate Antipsychotic Effect Without D2 Blockade
This pooled analysis of three short-term trials quantifies the efficacy of the first muscarinic agonist antipsychotic, which pharmacists will increasingly encounter as an alternative to dopamine D2 receptor antagonists in schizophrenia.
📅 Journal publication: Oct 2024(online Jan 10, 2025)·Last updated: Nov 15, 2026
KarXT shows promise for schizophrenia with a new mechanism of action.
KarXT offers a potential new class of treatment for schizophrenia by targeting muscarinic receptors rather than dopamine D2 receptors, potentially reducing typical side effects. KarXT demonstrated a significantly greater reduction in Positive and Negative Syndrome Scale (PANSS) scores versus placebo, with a least squares mean difference of -9.9 (P<0.0001). This study highlights KarXT’s potential to improve schizophrenia management, but longer-term studies are needed to confirm sustained efficacy and safety. KarXT shows promise as a new schizophrenia treatment targeting muscarinic receptors with significant symptom improvement.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Kaul I, Citrome L, Sawchak S, Kando J, Miller AC, Paul SM, Brannan SK
Citation:Kaul I, Citrome L, Sawchak S, et al. Efficacy of KarXT (Xanomeline Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. CNS spectrums. 2024;29(5):489-490. doi:10.1017/S1092852924001445